Yarrow Bioscience Inc YARW
News
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease